IN2015DN03796A - - Google Patents
Info
- Publication number
- IN2015DN03796A IN2015DN03796A IN3796DEN2015A IN2015DN03796A IN 2015DN03796 A IN2015DN03796 A IN 2015DN03796A IN 3796DEN2015 A IN3796DEN2015 A IN 3796DEN2015A IN 2015DN03796 A IN2015DN03796 A IN 2015DN03796A
- Authority
- IN
- India
- Prior art keywords
- gene signatures
- autoimmune disorders
- metabolic
- inflammation
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
This invention is related to the area of characterization of inflammation in relation with the gut microbiota in metabolic and autoimmune disorders. In particular it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases such as liver related metabolic disorders in particular to the evolution of benign steatosis towards its most severe forms (steatohepatitis and cirrhosis) or autoimmune disorders in particular inflammatory bowel diseases (Crohn's and Ulcerative Colitis). These gene signatures can therefore be used as a means of diagnosis prognosis stratification for drug studies for monitoring patient and for assigning an appropriate treatment.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12306286 | 2012-10-17 | ||
PCT/EP2013/071793 WO2014060555A1 (en) | 2012-10-17 | 2013-10-17 | Gene signatures of inflammatory disorders that relate to the liver |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN03796A true IN2015DN03796A (en) | 2015-10-02 |
Family
ID=47148686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3796DEN2015 IN2015DN03796A (en) | 2012-10-17 | 2013-10-17 |
Country Status (14)
Country | Link |
---|---|
US (2) | US10036074B2 (en) |
EP (1) | EP2909334B1 (en) |
JP (2) | JP6752016B2 (en) |
CN (1) | CN104769132B (en) |
AU (2) | AU2013333882B2 (en) |
BR (1) | BR112015008621A2 (en) |
CA (1) | CA2886748A1 (en) |
DK (1) | DK2909334T3 (en) |
ES (1) | ES2821383T3 (en) |
IL (1) | IL238025B (en) |
IN (1) | IN2015DN03796A (en) |
MX (1) | MX2015004844A (en) |
NZ (1) | NZ707035A (en) |
WO (1) | WO2014060555A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
CA3016059A1 (en) | 2016-03-04 | 2017-09-08 | The Regents Of The University Of California | Microbial consortium and uses thereof |
EP3445871A1 (en) * | 2016-04-20 | 2019-02-27 | Human Longevity, Inc. | Use of a microbiome profile to detect liver disease |
ES2871060T3 (en) * | 2016-05-11 | 2021-10-28 | Univ Southern California | Fasting mimicking diet (FMD) as an immunoregulatory treatment for autoimmune / inflammatory digestive diseases |
US11284640B2 (en) | 2017-02-14 | 2022-03-29 | University Of Southern California | Fasting mimicking diet |
CA3058943C (en) | 2017-04-03 | 2023-10-17 | Gusto Global, Llc | Rational design of microbial-based biotherapeutics |
CN107271674B (en) * | 2017-06-13 | 2019-05-07 | 首都医科大学附属北京地坛医院 | A kind of target marker GP73 and detection application method for steatohepatitis detection |
WO2019199895A1 (en) | 2018-04-10 | 2019-10-17 | Siolta Therapeutics, Inc. | Microbial consortia |
CN108504739A (en) * | 2018-05-15 | 2018-09-07 | 浙江大学 | A kind of biomarker and its application for hepatocarcinoma early diagnosis |
EP3899015A1 (en) * | 2018-12-19 | 2021-10-27 | Astrazeneca AB | Biomarker of pnpla3 expression |
CA3128973A1 (en) | 2019-03-04 | 2020-09-10 | Bhaskar Bhattacharyya | Data compression and communication using machine learning |
WO2021071864A1 (en) | 2019-10-07 | 2021-04-15 | Siolta Therapeutics, Inc. | Therapeutic pharmaceutical compositions |
CN111884792B (en) * | 2020-06-30 | 2021-07-09 | 深圳市永达电子信息股份有限公司 | System and method for preparing eigen-state network circuit signal based on memristor chaotic sequence |
US11688507B2 (en) | 2020-12-29 | 2023-06-27 | Kpn Innovations, Llc. | Systems and methods for generating a metabolic dysfunction nourishment program |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
US6610836B1 (en) * | 1999-01-29 | 2003-08-26 | Genome Therapeutics Corporation | Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics |
KR20020097200A (en) * | 2000-03-21 | 2002-12-31 | 엘리트라 파마슈티컬즈, 인코포레이티드 | Identification of essential genes in prokaryotes |
EP1227152A1 (en) * | 2001-01-30 | 2002-07-31 | Société des Produits Nestlé S.A. | Bacterial strain and genome of bifidobacterium |
ES2405405T3 (en) * | 2001-12-17 | 2013-05-31 | Corixa Corporation | Compositions and procedures for the therapy and diagnosis of inflammatory bowel disease |
US8119365B2 (en) * | 2002-01-23 | 2012-02-21 | Wisconsin Alumni Research Foundation | Insertion sequence-free bacteria |
JPWO2004092365A1 (en) * | 2003-04-13 | 2006-07-06 | 株式会社産学連携機構九州 | Extraction and selection method for hepatic disorder-related genes and evaluation and diagnosis of liver disorder or liver function using the same |
US7860656B2 (en) * | 2005-02-03 | 2010-12-28 | Assistance Publique-Hopitaux De Paris (Ap-Hp) | Diagnosis method of hepatic steatosis using biochemical markers |
WO2006089264A2 (en) * | 2005-02-18 | 2006-08-24 | Novartis Vaccines And Diagnostics Inc. | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
FR2893136A1 (en) * | 2005-11-10 | 2007-05-11 | Sanofi Aventis Sa | METHODS OF DIAGNOSING HEPATIC DISEASES AND SCREENING MOLECULES FOR THE TREATMENT OF THESE DISEASES |
US20110165568A1 (en) * | 2009-12-31 | 2011-07-07 | Life Technologies Corporation | Sequences of e.coli 055:h7 genome |
US20130045874A1 (en) * | 2010-03-01 | 2013-02-21 | Institut National De La Recherche Agronomique | Method of Diagnostic of Inflammatory Bowel Diseases |
JP5757032B2 (en) * | 2010-04-05 | 2015-07-29 | 学校法人東京医科大学 | Method for testing fibrosis of chronic liver disease using miRNA |
JP2012125215A (en) * | 2010-12-17 | 2012-07-05 | Osaka City Univ | Method for determining presence and/or severity of hepatic fibrosis, determining marker and kit used for determination, and method for predicting therapeutic effect of hepatic fibrosis, effect prediction marker, and kit used for effect prediction |
WO2012105590A1 (en) * | 2011-02-01 | 2012-08-09 | アステラス製薬株式会社 | Determination marker for non-alcoholic steatohepatitis, and method for diagnosing non-alcoholic steatohepatitis using the marker as measure |
WO2012159023A2 (en) * | 2011-05-19 | 2012-11-22 | Virginia Commonwealth University | Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction |
EP2763540A4 (en) * | 2011-09-09 | 2015-04-22 | Univ Yale | Compositions and methods for assessing and treating inflammatory diseases and disorders |
US20140377278A1 (en) * | 2012-01-10 | 2014-12-25 | Yale University | Compositions and Methods for Assessing and Treating Inflammatory Diseases and Disorders |
WO2014060538A1 (en) | 2012-10-17 | 2014-04-24 | Institut National De La Recherche Agronomique | Determination of reduced gut bacterial diversity |
WO2014060537A1 (en) | 2012-10-17 | 2014-04-24 | Institut National De La Recherche Agronomique | Prognostic of diet impact on obesity-related co-morbidities |
US20150284779A1 (en) | 2012-10-17 | 2015-10-08 | Institut National De La Recherche Agronomique | Determination of a tendency to gain weight |
US9459650B2 (en) | 2014-03-17 | 2016-10-04 | Qualcomm Incorporated | Clock pulse generator for multi-phase signaling |
-
2013
- 2013-10-17 US US14/435,750 patent/US10036074B2/en active Active
- 2013-10-17 WO PCT/EP2013/071793 patent/WO2014060555A1/en active Application Filing
- 2013-10-17 BR BR112015008621-7A patent/BR112015008621A2/en not_active Application Discontinuation
- 2013-10-17 DK DK13779214.9T patent/DK2909334T3/en active
- 2013-10-17 EP EP13779214.9A patent/EP2909334B1/en active Active
- 2013-10-17 ES ES13779214T patent/ES2821383T3/en active Active
- 2013-10-17 JP JP2015537267A patent/JP6752016B2/en not_active Expired - Fee Related
- 2013-10-17 MX MX2015004844A patent/MX2015004844A/en active IP Right Grant
- 2013-10-17 NZ NZ707035A patent/NZ707035A/en not_active IP Right Cessation
- 2013-10-17 CA CA2886748A patent/CA2886748A1/en not_active Abandoned
- 2013-10-17 CN CN201380054047.XA patent/CN104769132B/en not_active Expired - Fee Related
- 2013-10-17 AU AU2013333882A patent/AU2013333882B2/en not_active Ceased
- 2013-10-17 IN IN3796DEN2015 patent/IN2015DN03796A/en unknown
-
2015
- 2015-03-30 IL IL238025A patent/IL238025B/en active IP Right Grant
-
2018
- 2018-05-07 US US15/972,620 patent/US10626471B2/en active Active
-
2019
- 2019-03-05 JP JP2019039947A patent/JP2019092522A/en active Pending
- 2019-08-02 AU AU2019210666A patent/AU2019210666A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL238025B (en) | 2020-05-31 |
JP6752016B2 (en) | 2020-09-09 |
BR112015008621A2 (en) | 2018-08-28 |
CA2886748A1 (en) | 2014-04-24 |
US20180251819A1 (en) | 2018-09-06 |
CN104769132A (en) | 2015-07-08 |
US10036074B2 (en) | 2018-07-31 |
AU2013333882B2 (en) | 2019-05-16 |
MX2015004844A (en) | 2015-11-16 |
AU2013333882A1 (en) | 2015-05-07 |
EP2909334A1 (en) | 2015-08-26 |
ES2821383T3 (en) | 2021-04-26 |
JP2015535177A (en) | 2015-12-10 |
US10626471B2 (en) | 2020-04-21 |
CN104769132B (en) | 2018-05-08 |
US20160068890A1 (en) | 2016-03-10 |
JP2019092522A (en) | 2019-06-20 |
IL238025A0 (en) | 2015-05-31 |
EP2909334B1 (en) | 2020-06-24 |
WO2014060555A1 (en) | 2014-04-24 |
NZ707035A (en) | 2018-11-30 |
AU2019210666A1 (en) | 2019-08-22 |
DK2909334T3 (en) | 2020-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN03796A (en) | ||
CA2941917C (en) | Methods for the diagnosis and treatment of inflammatory bowel disease | |
MX2016002879A (en) | Systems, devices and methods for anti-tl1a therapy. | |
MA39963A (en) | Methods for treating inflammatory bowel disease | |
NZ602704A (en) | Method of diagnostic of inflammatory bowel diseases | |
MX2015015784A (en) | Methods for diagnosing and treating inflammatory bowel disease. | |
MX2017015210A (en) | Compositions and methods for screening solid tumors. | |
PH12016502167A1 (en) | Hdl theraphy markers | |
MX2022012384A (en) | Compositions and methods for screening mutations in thyroid cancer. | |
UA115540C2 (en) | Anti il-36r antibodies | |
IN2014MN01642A (en) | ||
MX2022010809A (en) | Methods for diagnosing and treating inflammatory bowel disease. | |
MX2017015700A (en) | Igfbp3 and uses thereof. | |
HK1159659A1 (en) | Treatment of autoimmune disease by modulating annexin-1 (lipocortin 1) -i( i) | |
BR112017014107A2 (en) | nutritional composition useful in treating patients with ibd | |
MA39710A (en) | Topical composition for use in the treatment of inflammatory bowel disease | |
MX344543B (en) | Methods and compositions for risk prediction, diagnosis, prognosis, and treatment of pulmonary disorders. | |
WO2015132670A3 (en) | Methods and compositions for detection of targets for autoimmune disease | |
EP3052661A4 (en) | Methods for assessing status of post-transplant liver and determining and administering specific treatment regimens | |
MX2022008842A (en) | Proteins for the treatment of epithelial barrier function disorders. | |
EP2852570A4 (en) | Compositions and methods for the treatment of inflammatory bowel disease | |
MA40592A (en) | Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies | |
HRP20190211T1 (en) | Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases | |
MX2017006959A (en) | Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease. | |
IN2014DN06662A (en) |